PI3K or AKT inhibitors may be used in CRC clinical trial with promising results, but drug resistance frequently appears, driven by β-catenin, which blocks FOXO 3A to induce apoptosis. The gene discussed is PIK3CA; the disease is colorectal carcinoma.